Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide.

Future cardiology - 1 Mar 2023

Sabbah Hani N, Taylor Carolyn, Vernon Hilary J

Abstract excerpt

Barth syndrome (BTHS) is a rare genetic disorder caused by pathogenic variants in TAFAZZIN leading to reduced remodeled cardiolipin (CL), a phospholipid essential to mitochondrial function and structure. Cardiomyopathy presents in most patients with BTHS, typically appearing as dilated cardiomyopathy (DCM) in infancy and evolving to hypertrophic cardiomyopathy (HCM) resembling heart failure (HF) with preserved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiolipins
Share to Heart Failure
Share to Phenotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Stroke Volume

Source

Identifiers

PMID: 37325898
DOI: 10.2217/fca-2023-0008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide.PMID 37325898Read ↗

Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.Semantic proximity Read ↗

The Role of Cardiolipin in Cardiovascular HealthSemantic proximity Read ↗

Use of Elamipretide in Patients Assigned Treatment in the Compassionate Use Program: Case Series in Four Rare Orphan DiseasesSemantic proximity Read ↗

Cardiolipin Remodeling Defects Impair Mitochondrial Architecture and Function in a Murine Model of Barth Syndrome Cardiomyopathy.Semantic proximity Read ↗

Clinical presentation and natural history of Barth Syndrome: An overview.Semantic proximity Read ↗

Pharmacogenomic considerations in the treatment of the pediatric cardiomyopathy called Barth syndrome.Semantic proximity Read ↗

New targets for monitoring and therapy in Barth syndrome.Semantic proximity Read ↗

Disturbed mitochondrial maturation in cardiolipin remodeling-deficient cardiomyocytesSemantic proximity Read ↗

Integrated Multi-Omics Mapping of Mitochondrial Dysfunction and Substrate Preference in Barth Syndrome Cardiac TissueSemantic proximity Read ↗

Metabolomic biomarkers from patients with Barth syndrome treated with elamipretide: insights from the TAZPOWER studySemantic proximity Read ↗

Deficient Cardiolipin Remodeling Alters Muscle Fiber Composition and Neuromuscular Connectivity in Barth SyndromeSemantic proximity Read ↗

A Barth Syndrome Patient-Derived D75H Point Mutation in TAFAZZIN Drives Progressive Cardiomyopathy in Mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.